Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy

Oncologist

Volumn 10, Issue 8, 2005, Pages 642-650

  Waltzman, Roger ^a   Croot, Christopher ^b   Justice, Glen R ^c   Fesen, Mark R ^d   Charu, Veena ^e   Williams, Denise ^f  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b North Mississippi Hematology and Oncology Associates   (United States)

^c Pacific Coast Hematology/Oncology Medical Group   (United States)

^d Hutchinson Clinic   (United States)

^e Pacific Cancer Medical Center   (United States)

^f Ortho Biotech Products LP   (United States)

Author keywords

Anemia; Cancer; Darbepoetin alfa; Epoetin alfa; Randomized trial; Transfusions

Indexed keywords

ANTINEOPLASTIC AGENT; FERROUS SULFATE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CARDIOPULMONARY INSUFFICIENCY; CAVA VEIN DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMATOCRIT; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STATISTICAL ANALYSIS; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOPHLEBITIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE;

EID: 26444555509     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-8-642     Document Type: Article

References (36)

1. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
2. Kallich JD, Tchekmedyian NS, Damiano AM et al. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park) 2002;16(suppl 10):117-124.
3. Bokemeyer C, Foubert J. Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol 2004;31(suppl 8):4-11.
4. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-519.
5. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
6. Ferrario E, Ferrari L, Bidoli P et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-575.
7. Jilani SM, Glaspy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol 1998;25:571-576.
8. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin alfa in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
9. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
10. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results of a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
11. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
12. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
13. Procrit® [package insert]. Raritan, NJ: Ortho Biotech Products, L.P., 2005.
14. Glaspy J, Colowick A, Heatherington A et al. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half life in oncology patients. Proc Am Soc Clin Oncol 2000;19:54a.
15. Tseng L, Schuller J, Mercer J et al. The pharmacokinetics of Aranesp™ in oncology patients undergoing multicycle chemotherapy. Blood 2000;96:156b.
16. Heatherington AC, Schuller J, Mercer AJ et al. The pharmacokinetics of darbepoetin alfa administered subcutaneously in patients with non-myeloid malignancies receiving multicycle chemotherapy. Blood 2001;98:298a.
17. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(suppl 3):3-13.
18. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
19. Glaspy JA, Jadeja JS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
20. Hesketh PJ, Arena F, Patel D et al. A randomized, controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-868.
21. Gabrilove J, Crawford J, Swan F et al. A multicenter study to assess the effects of darbepoetin alfa 200 mcg every 2 weeks (Q2W) in patients with nonmyeloid malignancies receiving chemotherapy: early results of the SURPASS Study. Blood 2003;102:19b.
22. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
23. Sabbatini P, Cella D, Chanan-Khan A et al. Cancer and treatment-related anemia. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, v.2.2004. Available at http://www.nccn.org.
24. Schwartzberg L, Shiffman R, Tomita D et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa in chemotherapy-induced anemia. Clin Ther 2003;25:2781-2796.
25. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. The Oncologist 2004;9:451-458.
26. Duh MS, Lefebvre P, Dector AJ et al. Weekly epoetin alfa (QW) provides similar hematologic outcomes to front-loading (FL) darbepoetin alfa regimens and better outcomes compared to darbepoetin alfa (Q2W) in patients with chemotherapy-related anemia. Blood 2003;102:511b-512b.
27. Rosberg J, Lefebvre P, Fastenau J et al. Clinical significance of a ≥1 g/dl rise in hemoglobin at week 4 or at week 8 during epoetin alfa therapy. Blood 2003;102:753a.
28. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2):13-19.
29. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
30. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
31. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
32. Liu Q, Chi GY. On sample size and inference for two-stage adaptive designs. Biometrics 2001;57:172-177.
33. Reed SH, Radeva JJ, Daniel D et al. The association of an early hemoglobin response with alternative metrics to evaluate efficacy of erythropoietic agents. Blood 2004;104:71a.
34. Papathefanis F, Fahrbach K, Mark T et al. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents. Proc Am Soc Clin Oncol 2004;23:552.
35. Jaresko G, Gibson G, Dominquez O et al. Evaluation of the use and outcomes of erythropoietic proteins for the treatment of chemotherapy-induced anemia in the university-affiliated ambulatory setting. Pharmacotherapy 2003;23:1345.
36. Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. The Oncologist 2004;9:696-707.